Baird BOS Advises ENT & Allergy of Delaware on Sale to Trinity Hunt
Baird’s Business Owner Solutions is pleased to announce that it served as the exclusive financial advisor to ENT & Allergy of Delaware (“ENTAD” or the “Company”), a leading comprehensive ear, nose and throat (“ENT”) and allergy provider, on its sale to private equity firm Trinity Hunt Partners (“Trinity Hunt”). ENTAD is the platform investment in Trinity Hunt’s newly launched portfolio company, Parallel ENT & Allergy Partners (“Parallel”). The combination of ENTAD and Parallel provides a physician-centric foundation for growth and a culture of high-quality clinical care, collaboration, and trust.
Founded in 2010, ENTAD operates out of three Delaware locations – Wilmington, Newark, and Middletown – with 15 physicians, 12 clinical audiologists, and over 140 support staff.
ENTAD was in advanced discussions with a select group of financial and strategic buyers and engaged Baird BOS to provide guidance on pricing and terms and ensure the transaction ultimately closed. Trinity Hunt was selected as the best partner for the practice moving forward due to cultural alignment and a shared vision for growth.
When asked about Baird’s role in the transaction, Dr. William Sheppard, Partner MD and Dr. Neil Hockstein, Partner MD of ENTAD commented, “Baird BOS’s extensive knowledge of the transaction process and market conditions was evident at every stage of the process. The BOS team negotiated improved pricing and terms and ensured the transaction closed expeditiously.”
Trinity Hunt Partners is a growth-oriented middle market private equity firm with over $1.2 billion of assets under management focused on partnering with business owners to build world-class business, healthcare, and consumer services companies.
About Baird Business Owner Solutions
Baird’s Business Owner Solutions team advises lower middle-market and emerging growth companies and their owners on business transition, valuation, and M&A transactions.
Jackson Barefoot, Director
Jason Spitz, Vice President
Shawn DeWeese, Analyst